Abstract 369P
Background
Whether germline BRCA (gBRCA) mutation affects prognosis and whether it has implications on treatment decision in the neoadjuvant setting is unclear.
Methods
Two centers retrospective cohort study comprising all women with early-stage TNBC who completed genetic testing and were treated with neoadjuvant chemotherapy with dose-dense chemotherapy containing carboplatin, between 10.2014 and 3.2020. Clinico-pathological features and data on dose reduction and delays were collected. Data on outcomes including pathological complete response (pCR), overall-survival (OS) and disease-free survival (DFS) were also calculated. Differences of these variables by gBRCA status were investigated.
Results
Sixty-four 64 women were included in the final analysis, of which 31 had pathogenic gBRCA mutation and 33 were gBRCA wild-type. Clinico-pathological characteristics and dose density and intensity were similar between both groups. Among gBRCA mutated patients, 23/31 (74%) achieved pCR, compared to 17/33 (51%) in the non-mutated, p=0.035. At a median follow-up of 30 months, gBRCA mutated women had significantly favorable OS (HR=8.64, 95% CI 1.08-69.21, p=0.042) and a trend for a favorable DFS (HR=7.4, 95% CI 0.91-60.27; p=0.062). The favorable OS for gBRCA mutated women remained significant in multivariate analysis (p=0.029) and was noted regardless to pathological response (p=0.01).
Conclusions
Compared to non-mutated, gBRCA mutated women with locally advanced TNBC treated with neoadjuvant chemotherapy containing carboplatin had a higher pCR rate and better outcome. Whether gBRCA mutation has a role in deescalating treatment in this population, should be further investigated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Goldvaser: Financial Interests, Personal, Speaker, Consultant, Advisor, Not related to the submitted work: Gilead, Oncotest , Novartis ; Financial Interests, Personal, Advisory Board, Not related to the submitted work: Pfizer; Financial Interests, Personal, Invited Speaker, Not related to the submitted work: Roche , AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD. R. Yerushalmi: Financial Interests, Personal, Speaker, Consultant, Advisor, outside the submitted work: Roche, Eli-Lilly ; Financial Interests, Institutional, Research Grant, outside the submitted work: Roche; Financial Interests, Personal, Advisory Board, outside the submitted work: Pfizer, Novartis, Gilead; Financial Interests, Personal, Invited Speaker, outside the submitted work: Medison, MSD, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
359P - Unveiling the factors influencing exercise engagement in breast cancer patients: Insights from the early recovery phase
Presenter: Sujin Yeon
Session: Poster session 03
360P - Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Presenter: Yue Chai
Session: Poster session 03
361P - A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer
Presenter: Jing Wu
Session: Poster session 03
362P - CYBERNEO trial: Update of results at 14 years of follow-up
Presenter: Syrine Ben Dhia
Session: Poster session 03
363P - High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome
Presenter: Larissa Mont'Alverne Arruda
Session: Poster session 03
365P - Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study
Presenter: Baocheng Wang
Session: Poster session 03
366P - Artificial intelligence (AI)-powered assessment of complete and intense human epidermal growth factor receptor 2 (HER2)-positive tumor cell proportion in breast cancer: Predicting fluorescence in situ hybridization (FISH) positivity and response to HER2-targeted therapy
Presenter: Minsun Jung
Session: Poster session 03
367P - Sentinel lymph node biopsy (SLNB) in patients with locally advanced breast cancer (LABC): Descriptive, inferential and survival analysis
Presenter: Johanna Espejo Niño
Session: Poster session 03
368P - Impact of PET-CT-determined sarcopenia on survival and pathological complete response in breast cancer patients with neoadjuvant chemotherapy
Presenter: Gözde Tahtaci
Session: Poster session 03
370P - LYMPHA surgery to reduce lymphedema following axillary node clearance: A new study at a London plastics centre
Presenter: Dorian Hobday
Session: Poster session 03